Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03324776 · ClinicalTrials.gov registry record · Phase 3

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

A Phase 3 study of Type 2 Diabetes, sponsored by Model Clinical Research.

Completed
Registry status
Phase 3
Development phase
20
Enrollment target
1
Study location

NCT03324776: Completed Phase 3 study of Type 2 Diabetes, sponsored by Model Clinical Research.

NCT03324776 is a Phase 3 study of Type 2 Diabetes that has completed, run by Model Clinical Research. The registered enrollment target is 20 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03324776, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by Model Clinical Research.

COMPLETED
Registry status
Phase 3
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.

Primary Outcome

Change in percentage of HbA1c from baseline to 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher and 11.5% or lower

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Afrezza Inhalant Product

Study Locations (1)

Maryland

  • MODEL Clinical Research - Baltimore

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2017-10-16
Est. Completion 2020-06-10
Phase Phase 3
Model Clinical Research

1 total trials

What the finished NCT03324776 record still lists

NCT03324776 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Afrezza Inhalant Product is the first listed.

NCT03324776 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT03324776 about?

NCT03324776 is a clinical study titled "Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients". To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.

What is the current status of trial NCT03324776?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2017-10-16. Estimated completion is 2020-06-10.

What conditions does trial NCT03324776 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT03324776?

The interventions under investigation include: Afrezza Inhalant Product (DRUG).

Who is sponsoring clinical trial NCT03324776?

This trial is sponsored by Model Clinical Research, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03324776 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03324776's enrollment target sits among peer trials

20 290th of 327 higher than 23 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03324776, the US trial registry maintained by the National Library of Medicine. NCT03324776 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.